- Home
- VRAX vs CSCI Comparison
VRAX vs CSCI Comparison
Compare VRAX & CSCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- CSCI
- Stock Information
- Founded
- VRAX 2013
- CSCI 1990
- Country
- VRAX United Kingdom
- CSCI Canada
- Employees
- VRAX N/A
- CSCI N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CSCI
- Sector
- VRAX Health Care
- CSCI
- Exchange
- VRAX Nasdaq
- CSCI NYSE
- Market Cap
- VRAX 7.3M
- CSCI 8.5M
- IPO Year
- VRAX 2022
- CSCI 1996
- Fundamental
- Price
- VRAX $1.87
- CSCI $2.72
- Analyst Decision
- VRAX
- CSCI
- Analyst Count
- VRAX 0
- CSCI 0
- Target Price
- VRAX N/A
- CSCI N/A
- AVG Volume (30 Days)
- VRAX 304.3K
- CSCI 8.2K
- Earning Date
- VRAX 02-05-2025
- CSCI 03-26-2025
- Dividend Yield
- VRAX N/A
- CSCI N/A
- EPS Growth
- VRAX N/A
- CSCI N/A
- EPS
- VRAX N/A
- CSCI N/A
- Revenue
- VRAX $84,872.00
- CSCI $4,834,000.00
- Revenue This Year
- VRAX $5,169.18
- CSCI N/A
- Revenue Next Year
- VRAX $66.97
- CSCI N/A
- P/E Ratio
- VRAX N/A
- CSCI N/A
- Revenue Growth
- VRAX 7.03
- CSCI N/A
- 52 Week Low
- VRAX $0.60
- CSCI $2.38
- 52 Week High
- VRAX $9.00
- CSCI $11.10
- Technical
- Relative Strength Index (RSI)
- VRAX 48.66
- CSCI N/A
- Support Level
- VRAX $1.65
- CSCI N/A
- Resistance Level
- VRAX $2.10
- CSCI N/A
- Average True Range (ATR)
- VRAX 0.22
- CSCI 0.00
- MACD
- VRAX 0.01
- CSCI 0.00
- Stochastic Oscillator
- VRAX 42.47
- CSCI 0.00
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About CSCI COSCIENS BIOPHARMA INC
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries. The company is engaged in the development of therapeutic assets and proprietary extraction technology.